Magellan Rx first to innovate with Medicaid VBC solutions for states grappling with the high cost of novel cell and gene therapies

Prime celebrates 25th anniversary, and Magellan Rx celebrates 10th anniversary

In late 2023, the FDA approved a new treatment regimen for urothelial cancer that represents a “paradigm change,” according to one industry expert

Nicole Grevenitz, director of clinical account services, shares more from the research study “Promoting Health Equity Through Enhanced, Personalized Digital Outreach.”